He says the peptide has almost no human data and is only sold online as a research chemical, so both the compound and its sourcing carry unknown risks.
Recap by typeshit. Full story at Cleveland Clinic Health Essentials.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
Online sellers pitch peptides for weight loss, anti-aging and muscle gain, and Gavin Coote's full story looks at the risks of products nobody regulates.
Mounjaro held 86.7% of Korea's GLP-1 weight loss market in June, and Hanmi's homegrown Eppe was just approved in five strengths.
Lilly shared new Phase 3b findings involving its psoriasis drug Taltz together with Zepbound. The wire post gives few specifics.
Loading…